- Investing Ideas
- Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Hong Kong Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
7
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
7 companies
Innovent Biologics
Market Cap: HK$149.7b
A biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, Europe, and internationally.
1801
HK$86.00
7D
-3.7%
1Y
-7.4%
CanSino Biologics
Market Cap: HK$9.8b
Develops, manufactures, and commercializes vaccines in the People’s Republic of China.
6185
HK$23.14
7D
-1.1%
1Y
-47.8%
Akeso
Market Cap: HK$84.6b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$91.85
7D
-6.8%
1Y
-39.6%
Biocytogen Pharmaceuticals (Beijing)
Market Cap: HK$48.1b
A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.
2315
HK$52.45
7D
-3.0%
1Y
99.1%
InSilico Medicine Cayman TopCo
Market Cap: HK$24.1b
Engages in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms.
3696
HK$42.02
7D
-12.0%
1Y
n/a
Frontage Holdings
Market Cap: HK$2.5b
Provides drug discovery, drug development, pharmaceutical product development, and laboratory testing services to pharmaceutical, biotechnology, and agrochemical companies.
1521
HK$1.21
7D
5.2%
1Y
-17.1%
WuXi XDC Cayman
Market Cap: HK$66.0b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$52.15
7D
-4.0%
1Y
-9.4%